← Browse by Condition

Medical Condition

pulmonary hypertension

Total Trials

25

Recruiting Now

25

Trial Phases

Phase 3, EARLY_Phase 1, Phase 2

Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.

Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.

Frequently Asked Questions — pulmonary hypertension Clinical Trials

How many clinical trials are currently recruiting for pulmonary hypertension?

ClinicalMetric currently tracks 25 actively recruiting clinical trials for pulmonary hypertension, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 25. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for pulmonary hypertension?

pulmonary hypertension research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a pulmonary hypertension clinical trial?

Eligibility criteria for pulmonary hypertension trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

1

Phase 2

2

Phase 3

1

Top Sponsors

Mayo Clinic 2 trials

Louisiana State University Health Sciences Center in New Orleans 1 trial

Medical University of Graz 1 trial

Gradient Denervation Technologies 1 trial

Golden Jubilee National Hospital 1 trial

Recruiting Clinical Trials

New Orleans Pulmonary Hypertension Biobank

Louisiana State University Hea...

Database for Clinical and Anamnestic Data in Pulmonary Hypertension

Medical University of Graz

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)

Gradient Denervation Technolog...

Accuracy of Smartwatches in Measuring Oxygen Levels in Patients With Pulmonary Hypertension: A Pilot Study

Golden Jubilee National Hospit...

Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC

The Hospital for Sick Children

NCT05844462 Phase 3

Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease

Assistance Publique - Hôpitaux...

Rutgers University Study of the Genetics of Pulmonary Hypertension

Rutgers, The State University ...

Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography

Royal United Hospitals Bath NH...

Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension

University of Sao Paulo Genera...

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass

University of Pennsylvania

Phenotyping Resting and Exertional Right Ventricular Dysfunction Among Patients With Chronic Obstructive Pulmonary Disease

University of Colorado, Denver

NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot

St. Olavs Hospital

Real-World Study of PADN for the Treatment of PAH

Pulnovo Medical (Wuxi) Co., Lt...

Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

Peking Union Medical College H...

PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

University Health Network, Tor...

Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis

Alejandro Cruz Utrilla

Real World Observational Study of Sotatercept for Pulmonary Hypertension

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NCT07837830 EARLY_Phase 1

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

Valley Health System

NCT03630211 Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

University of Rochester

Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope

Eko Devices, Inc.

NCT06570473 Phase 2

Feasibility Trial for a Right Ventricular Failure Platform Trial

University of Alberta

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Johns Hopkins University

CVD/PH and Voice Characteristics

Related Conditions

systemic sclerosis (2) pulmonary arterial hypertension pah who group 1 ph (2) right ventricular dysfunction (2) interstitial lung disease (2) mixed connective tissue disease (1) heart failure with normal ejection fraction (1) healthy (1) bpd bronchopulmonary dysplasia (1) nec (1) chronic obstructive pulmonary disease (1) pulmonary arterial hypertension (1) pulmonary arterial hypertension associated with connective tissue disease (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology